)
Visual
test
BioRestorative Therapies
BioRestorative Therapies (BRTX) investor relations material
BioRestorative Therapies Registration Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration Filing summary18 Nov, 2025
Company overview and business model
Develops therapeutic products using cell and tissue protocols, focusing on adult stem cells for disc/spine disease and metabolic disorders, and operates a commercial biocosmeceutical platform.
Lead product BRTX-100 targets non-surgical treatment of lumbosacral disc disorders; Phase 2 clinical trial underway for chronic lower back pain.
Metabolic program (ThermoStem) develops cell-based therapies for obesity and metabolic disorders using brown adipose-derived stem cells; holds patents in the US and other jurisdictions.
Commercial biocosmeceutical product is a cell-based secretome serum for cosmetic applications, with plans to expand into additional biologic aesthetic products.
Financial performance and metrics
As of November 17, 2025, 8,876,242 shares of common stock were outstanding, with 1,398,158 shares of Series B preferred stock issued and outstanding.
The closing sale price for common stock on November 17, 2025, was $1.24 per share on NASDAQ Capital Market.
If all outstanding warrants are exercised, gross proceeds would be $1,398,628, intended for general corporate purposes and working capital.
Use of proceeds and capital allocation
Will not receive proceeds from the sale of shares by selling securityholders; proceeds from warrant exercises, if any, will be used for general corporate purposes and working capital, including clinical trials and business initiatives.
Address going concern warning and mitigation
Impact of warrant exercise price on capital?
Biocosmeceutical strategy: commercial vs. FDA
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- PTC
Q1'26 saw double-digit ARR growth, margin gains, and major buybacks, with a strong FY'26 outlook. - ARM
Q3 revenue up 26% YoY, driven by Armv9, AI, and data center growth; margins remain strong. - SITM
Q4 2025 revenue jumped 66% year-over-year, with CED growth and a major acquisition fueling momentum. - NTGR
Record margins and revenue growth in 2025, with memory risks and margin pressure ahead. - CLFD
Net sales up 16% to $34.3M, gross margin improved, Nova Platform launched, guidance reaffirmed. - MCK
Q3 revenue up 11%, adjusted EPS up 16%, and fiscal 2026 EPS guidance raised to $38.80–$39.20. - ASGN
Q4 revenue hit $980.1M; rebranding and $290M Quinnox acquisition to drive digital growth. - MC
Record 2025 revenue and earnings growth, strong capital returns, and new $300M buyback. - RM
Record net income, revenue, and portfolio growth with improved efficiency and strong outlook. - SNAP
Q4 2025 revenue up 10%, net income $45M, MAUs 946M, and $500M buyback announced.
Next BioRestorative Therapies earnings date
Q4 202527 Mar, 2026
BioRestorative Therapies
Next BioRestorative Therapies earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BioRestorative Therapies Inc is a biotechnology company focused on developing regenerative medicine therapies, particularly for musculoskeletal and metabolic conditions. The company’s research centers on stem cell-based treatments designed to address chronic lower back pain, degenerative disc disease, and metabolic disorders. BioRestorative Therapies leverages its proprietary stem cell platforms to create potential therapeutic options that aim to repair and regenerate damaged tissues, supporting patients with limited treatment alternatives. The company is headquartered in Melville, New York, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage